HIV-1 Protease Inhibitors from Inverse Design in the Substrate Envelope Exhibit Subnanomolar Binding to Drug-Resistant Variants was written by Altman, Michael D.;Ali, Akbar;Reddy, G. S. Kiran Kumar;Nalam, Madhavi N. L.;Anjum, Saima Ghafoor;Cao, Hong;Chellappan, Sripriya;Kairys, Visvaldas;Fernandes, Miguel X.;Gilson, Michael K.;Schiffer, Celia A.;Rana, Tariq M.;Tidor, Bruce. And the article was included in Journal of the American Chemical Society in 2008.HPLC of Formula: 321309-26-6 This article mentions the following:
The acquisition of drug-resistant mutations by infectious pathogens remains a pressing health concern, and the development of strategies to combat this threat is a priority. Here the authors have applied a general strategy, inverse design using the substrate envelope, to develop inhibitors of HIV-1 protease. Structure-based computation was used to design inhibitors predicted to stay within a consensus substrate volume in the binding site. Two rounds of design, synthesis, exptl. testing, and structural anal. were carried out, resulting in a total of 51 compounds Improvements in design methodol. led to a roughly 1000-fold affinity enhancement to a wild-type protease for the best binders, from a Ki of 30-50 nM in round one to below 100 pM in round two. Crystal structures of a subset of complexes revealed a binding mode similar to each design that respected the substrate envelope in nearly all cases. All four best binders from round one exhibited broad specificity against a clin. relevant panel of drug-resistant HIV-1 protease variants, losing no more than 6-13-fold affinity relative to wild type. Testing a subset of second-round compounds against the panel of resistant variants revealed three classes of inhibitors: robust binders (maximum affinity loss of 14-16-fold), moderate binders (35-80-fold), and susceptible binders (greater than 100-fold). Although for especially high-affinity inhibitors addnl. factors may also be important, overall, these results suggest that designing inhibitors using the substrate envelope may be a useful strategy in the development of therapeutics with low susceptibility to resistance. In the experiment, the researchers used many compounds, for example, 5-Methyl-4-isoxazolesulfonyl chloride (cas: 321309-26-6HPLC of Formula: 321309-26-6).
5-Methyl-4-isoxazolesulfonyl chloride (cas: 321309-26-6) belongs to isoxazole derivatives. An isoxazolyl group is found in many beta-lactamase-resistant antibiotics, such as cloxacillin, dicloxacillin and flucloxacillin. As with isoxazolines, isoxazoles may be cleaved using low-valent titanium obtained from the Kulinkovich reaction.This procedure affords enaminoketones from 2,4-substituted isoxazoles.HPLC of Formula: 321309-26-6
Referemce:
Isoxazole – Wikipedia,
Isoxazole | C3H3NO – PubChem